Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms

Leukemia Research

Volumn 38, Issue 8, 2014, Pages 896-900

  Tang, Guilin ^a   Wang, Sa A ^a   Lu, Victoria ^a   Lee, Hans Chulhee ^a   Qazilbash, Muzaffar H ^a   Wang, Xiaohong I ^a   Yin, C Cameron ^a   Orlowski, Robert ^a   Wang, Yaping ^a   Patel, Ankita ^b   Medeiros, L Jeffrey ^a   Lu, Gary ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bone marrow; Clonal cytogenetic abnormalities; Cytotoxic therapy; Silent; Therapy related myeloid neoplasms

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; FOLINIC ACID; MELPHALAN; MESNA; METHOTREXATE; PREDNISONE; RITUXIMAB; STEROID; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; CHILD; CHROMOSOME 20Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATIONAL STUDY; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; LYMPHOCYTOTOXICITY; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; MOLECULAR CLONING; MULTIPLE MYELOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SILENT CLONAL CYTOGENETIC ABNORMALITY;

BONE MARROW; CLONAL CYTOGENETIC ABNORMALITIES; CYTOTOXIC THERAPY; SILENT; THERAPY-RELATED MYELOID NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY;

EID: 84904550541     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.05.015     Document Type: Article

References (23)

1. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, International Agency for Research on Cancer, Lyon.
2. Basecke J., Podleschny M., Becker A., Seiffert E., Schwiers I., Schwiers R., et al. Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma. Br J Haematol 2008, 141(1):52-59.
3. Lopez de Mesa R., Sierrasesumaga L., Calasanz M.J., Lopez de Cerain A.L., Patino-Garcia A. Nonclonal chromosomal aberrations induced by anti-tumoral regimens in childhood cancer: relationship with cancer-related genes and fragile sites. Cancer Genet Cytogenet 2000, 121(1):78-85.
4. Martinez-Climent J.A., Comes A.M., Vizcarra E., Benet I., Arbona C., Prosper F., et al. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome. Bone Marrow Transplant 2000, 25(11):1203-1208.
5. Wiktor A., Rybicki B.A., Piao Z.S., Shurafa M., Barthel B., Maeda K., et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 2000, 27(1):11-16.
6. Tang G., Jorgensen J.L., Zhou Y., Hu Y., Kersh M., Garcia-Manero G., et al. Multi-color CD34(+) progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. Leuk Res 2012, 36(8):974-981.
7. Shaffer L.G., McGowan-Jordan J., Schmid M. ISCN 2013: an international system for human cytogenetic nomenclature (2013). Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature 2013, Medical and Scientific Publishers, Karger.
8. Sandoval C., Mayer S.P., Giamelli J., Farley T., Ozkaynak M.F., Tugal O., et al. Cytogenetic abnormalities during clinical, immunophenotypic, and molecular remission in pediatric acute lymphoblastic leukemia. Cancer Genet Cytogenet 2000, 118(1):9-13.
9. Andreasson P., Johansson B., Arheden K., Tedgard U., Ljung R., Heim S., et al. Emergence of novel transient clonal chromosomal bone marrow changes in remission of acute lymphoblastic leukemia. Leukemia 1996, 10(2):378-383.
10. Wang H., Jin J., Wang Y., Huang X., Huang J. Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy. Ann Hematol 2013, Epub.
11. Deininger M.W., Cortes J., Paquette R., Park B., Hochhaus A., Baccarani M., et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007, 110(7):1509-1519.
12. Jabbour E., Kantarjian H.M., Abruzzo L.V., O'Brien S., Garcia-Manero G., Verstovsek S., et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007, 110(8):2991-2995.
13. Ok C.Y., Hasserjian R.P., Fox P.S., Stingo F., Zuo Z., Young K.H., et al. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 2014, 28(1):185-189.
14. Hanson C.A., Steensma D.P., Hodnefield J.M., Nguyen P.L., Hoyer J.D., Viswanatha D.S., et al. Isolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance. Am J Clin Pathol 2008, 129(3):478-485.
15. Alimena G., Breccia M., Mancini M., Ferranti G., De Felice L., Gallucci C., et al. Clonal evolution in Philadelphia chromosome negative cells following successful treatment with imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome. Leukemia 2004, 18(2):361-362.
16. Terre C., Eclache V., Rousselot P., Imbert M., Charrin C., Gervais C., et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004, 18(8):1340-1346.
17. Medina J., Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Giles F., et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003, 98(9):1905-1911.
18. O'Shea D., Crotty G., Carroll P., Conneally E., McCann S., Neat M.J. Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance?. Br J Haematol 2004, 127(3):367-369.
19. Gupta R., Soupir C.P., Johari V., Hasserjian R.P. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol 2007, 139(2):265-268.
20. Braun T., de Botton S., Taksin A.L., Park S., Beyne-Rauzy O., Coiteux V., et al. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leuk Res 2011, 35(7):863-867.
21. Kanagal-Shamanna R., Yin C.C., Miranda R.N., Bueso-Ramos C.E., Wang X.I., Muddasani R., et al. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q). Cancer Genet 2013, 206(1-2):42-46.
22. Pegram L.D., Megonigal M.D., Lange B.J., Nowell P.C., Rowley J.D., Rappaport E.F., et al. t(3;11) translocation in treatment-related acute myeloid leukemia fuses MLL with the GMPS (guanosine 5' monophosphate synthetase) gene. Blood 2000, 96(13):4360-4362.
23. Rowley J.D., Reshmi S., Sobulo O., Musvee T., Anastasi J., Raimondi S., et al. All patients with the t(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 1997, 90(2):535-541.